Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood.

Abstract:

BACKGROUND:A lack of reliable treatments for abdominal pain-related functional gastrointestinal disorders prompts interest in new therapies. AIM:To evaluate systematically the effect of Lactobacillus rhamnosus GG (LGG) for treating abdominal pain-related functional gastrointestinal disorders in children. METHODS:MEDLINE, EMBASE, CINAHL, the Cochrane Library, trial registries and proceedings of major meetings were searched for randomised controlled trials (RCTs) evaluating LGG supplementation in children with abdominal pain-related functional gastrointestinal disorders based on the Rome II or Rome III criteria. Risk of bias was assessed for generation of the allocation sequence, allocation concealment, blinding and follow-up. RESULTS:Compared with placebo, LGG supplementation was associated with a significantly higher rate of treatment responders (defined as no pain or a decrease in pain intensity) in the overall population with abdominal pain-related functional gastrointestinal disorders (three RCTs, n = 290; risk ratio, RR 1.31, 95% CI 1.08-1.59, number needed to treat, NNT 7, 95% CI 4-22) and in the irritable bowel syndrome (IBS) subgroup (three RCTs, n = 167; RR 1.70, 95% CI 1.27-2.27, NNT 4, 95% CI 3-8). However, no difference was found in the rate of treatment responders between children with functional abdominal pain or functional dyspepsia who received placebo or LGG. The intensity of pain was significantly reduced in the overall study population and in the IBS subgroup. The frequency of pain was significantly reduced in the IBS subgroup only. CONCLUSION:The use of Lactobacillus rhamnosus GG moderately increases treatment success in children with abdominal pain-related functional gastrointestinal disorders, particularly among children with IBS.

journal_name

Aliment Pharmacol Ther

authors

Horvath A,Dziechciarz P,Szajewska H

doi

10.1111/j.1365-2036.2011.04665.x

subject

Has Abstract

pub_date

2011-06-01 00:00:00

pages

1302-10

issue

12

eissn

0269-2813

issn

1365-2036

journal_volume

33

pub_type

杂志文章,meta分析
  • Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis.

    abstract:BACKGROUND:Long-acting somatostatin analogues have been suggested as an alternative to propranolol for the prevention of variceal rebleeding. AIM:To compare the effectiveness of lanreotide SR, a new depot formulation injected once-weekly, and propranolol in reducing circadian portal blood flow (PVF) and meal-stimulate...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2003.01682.x

    authors: Schiedermaier P,Koch L,Stoffel-Wagner B,Layer G,Sauerbruch T

    更新日期:2003-10-15 00:00:00

  • Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients.

    abstract:BACKGROUND:Liver cirrhosis is characterized by a silent phase until decompensation, which is defined by ascites, bleeding from esophageal varices or hepatic encephalopathy. AIM:To compare the clinical course, patterns of survival and causes of death by etiology during long-term follow-up in a large population-based co...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15255

    authors: Nilsson E,Anderson H,Sargenti K,Lindgren S,Prytz H

    更新日期:2019-06-01 00:00:00

  • Review article: 'true' re-infection of Helicobacter pylori after successful eradication--worldwide annual rates, risk factors and clinical implications.

    abstract:BACKGROUND:The incidence of 'true' re-infection with Helicobacter pylori after successful eradication remains uncertain. AIM:To determine the worldwide rates, risk factors and clinical implications of 'true' re-infection of Helicobacter pylori. 'True' re-infection of H. pylori is defined as the situation where tests f...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2008.03873.x

    authors: Zhang YY,Xia HH,Zhuang ZH,Zhong J

    更新日期:2009-01-01 00:00:00

  • Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy.

    abstract:BACKGROUND:Spontaneous portosystemic shunt (SPSS) is a frequent cause of recurrent hepatic encephalopathy (HE) in patients with cirrhosis. AIM:To assess the effectiveness and optimal candidate selection for embolisation of SPSS, for the treatment of recurrent HE in patients with cirrhosis. METHODS:This retrospective ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12771

    authors: An J,Kim KW,Han S,Lee J,Lim YS

    更新日期:2014-06-01 00:00:00

  • Incidence, clinical presentation and mortality of liver cirrhosis in Southern Sweden: a 10-year population-based study.

    abstract:BACKGROUND:In Sweden, the most common causes of liver cirrhosis are alcohol overconsumption and hepatitis C. However, recent data on the clinical characteristics of Swedish patients with cirrhosis are scarce. AIMS:To determine the incidence, clinical presentation, aetiological spectrum and survival rates of liver cirr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13635

    authors: Nilsson E,Anderson H,Sargenti K,Lindgren S,Prytz H

    更新日期:2016-06-01 00:00:00

  • Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.

    abstract:BACKGROUND:Regulatory requirements for claims of mucosal healing in ulcerative colitis (UC) will require demonstration of both endoscopic and histologic healing. Quantifying these rates is essential for future drug development. AIMS:To meta-analyse endoscopic and histologic placebo response and remission rates in UC r...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/apt.14672

    authors: Ma C,Guizzetti L,Panaccione R,Fedorak RN,Pai RK,Parker CE,Nguyen TM,Khanna R,Vande Casteele N,D'Haens G,Sandborn WJ,Feagan BG,Jairath V

    更新日期:2018-06-01 00:00:00

  • Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects.

    abstract:BACKGROUND:In rheumatoid arthritis and psoriasis female sex has been shown to be associated with discontinuation of anti-tumour necrosis factor-α (TNF-α) therapy. AIM:To retrospectively assess the association between sex and TNF-α drug persistence in patients with inflammatory bowel disease (IBD). METHODS:All IBD pat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15380

    authors: Schultheiss JPD,Brand EC,Lamers E,van den Berg WCM,van Schaik FDM,Oldenburg B,Fidder HH

    更新日期:2019-08-01 00:00:00

  • A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.

    abstract:BACKGROUND:Pancreatic enzyme replacement therapy (PERT) is necessary to prevent severe maldigestion and unwanted weight loss associated with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery (PS). AIM:To assess the long-term safety and efficacy of pancrelipase (pancreatin) ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2011.04631.x

    authors: Gubergrits N,Malecka-Panas E,Lehman GA,Vasileva G,Shen Y,Sander-Struckmeier S,Caras S,Whitcomb DC

    更新日期:2011-05-01 00:00:00

  • Review article: liver transplantation for the pulmonary disorders of portal hypertension.

    abstract:BACKGROUND:Liver transplantation is potentially a life-saving therapeutic intervention for patients with portopulmonary hypertension and hepatopulmonary syndrome. However, due to limited data, listing criteria for patients with these conditions have not been clearly established. Indeed, this has led some to speculate t...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.12140

    authors: Houlihan DD,Holt A,Elliot C,Ferguson JW

    更新日期:2013-01-01 00:00:00

  • Relationship between the Fibrotest and portal hypertension in patients with liver disease.

    abstract:BACKGROUND:The best technique to estimate portal hypertension (PHT) is to measure the hepatic venous pressure gradient (HVPG), which is an invasive method. AIM:To assess the relationship between the Fibrotest (Biopredictive, Paris, France) and the presence and degree of PHT in patients with liver disease, and to deter...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2007.03378.x

    authors: Thabut D,Imbert-Bismut F,Cazals-Hatem D,Messous D,Muntenau M,Valla DC,Moreau R,Poynard T,Lebrec D

    更新日期:2007-08-01 00:00:00

  • Effects of lactulose and polyethylene glycol on colonic transit.

    abstract:BACKGROUND:The effects of lactulose and polyethylene glycol on colonic transit are poorly established. AIM:To assess the effects of these laxatives on colonic transit in normal subjects. METHODS:Colonic transit (mean residence time, cumulative counts in stool, counts remaining in the proximal or distal colon) was mea...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.2005.02244.x

    authors: Fritz E,Hammer HF,Lipp RW,Högenauer C,Stauber R,Hammer J

    更新日期:2005-02-01 00:00:00

  • Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients.

    abstract:BACKGROUND:Steroid-refractory ulcerative colitis (UC) remains a challenging condition warranting surgery upon failure of pharmacological treatment. Calcineurin inhibitors or infliximab are alternatives in this situation. Data on the efficacy and safety of tacrolimus in this setting are limited. AIM:To study the short-...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12118

    authors: Schmidt KJ,Herrlinger KR,Emmrich J,Barthel D,Koc H,Lehnert H,Stange EF,Fellermann K,Büning J

    更新日期:2013-01-01 00:00:00

  • Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs.

    abstract:BACKGROUND:The use of non-steroidal anti-inflammatory drugs (NSAIDs) is often associated with upper gastrointestinal symptoms such as heartburn and acid regurgitation. AIM:To assess the efficacy of esomeprazole 20 and 40 mg for resolution of heartburn and acid regurgitation in continuous NSAIDs. METHODS:A post hoc an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/j.1365-2036.2006.03210.x

    authors: Hawkey CJ,Jones RH,Yeomans ND,Scheiman JM,Talley NJ,Goldstein JL,Ahlbom H,Naesdal J

    更新日期:2007-04-01 00:00:00

  • A single night-time dose of famotidine is equivalent to ranitidine in decreasing 24-hour gastric acidity in asymptomatic duodenal ulcer subjects.

    abstract::Six asymptomatic, non-smoking men with endoscopically proven duodenal ulcer disease received single nocturnal doses of placebo, 40 mg famotidine and 300 mg ranitidine each for 1 week prior to serial measurement of pH, peptic activity and serum gastrin concentrations over 24 h and of acid output. The intragastric pH fl...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1989.tb00206.x

    authors: Thomson AB,Pinchbeck BR,Kirdeikis J,Zuk L,Marriage B,Prat A

    更新日期:1989-04-01 00:00:00

  • Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?

    abstract:BACKGROUND:The presence of the gastric pathogen, Helicobacter pylori influences acid suppression by proton pump inhibitors and treatment outcome in patients with gastro-oesophageal reflux disease. AIM:To determine the influence of H. pylori infection on effectiveness of rabeprazole in primary and secondary care patien...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2004.02096.x

    authors: Wit NJ,Boer WA,Geldof H,Hazelhoff B,Bergmans P,Tytgat GN,Smout AJ

    更新日期:2004-08-15 00:00:00

  • Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

    abstract:BACKGROUND:Programmed cell death protein-1-targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma. AIM:To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real-world cohort of patients with advanced hepatocellular carcinoma. METH...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.15245

    authors: Scheiner B,Kirstein MM,Hucke F,Finkelmeier F,Schulze K,von Felden J,Koch S,Schwabl P,Hinrichs JB,Waneck F,Waidmann O,Reiberger T,Müller C,Sieghart W,Trauner M,Weinmann A,Wege H,Trojan J,Peck-Radosavljevic M,Vogel A

    更新日期:2019-05-01 00:00:00

  • Review article: esomeprazole in the treatment of Helicobacter pylori.

    abstract::Proton pump inhibitor-based triple therapy is the most commonly used treatment for eradication of Helicobacter pylori, with pooled eradication rates of approximately 90%. In the USA, per protocol eradication rates with 10-day proton pump inhibitor-based triple therapy are approximately 85%. Esomeprazole, a new proton ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.16.s4.13.x

    authors: Laine L

    更新日期:2002-07-01 00:00:00

  • Review article: inflammatory bowel disease--empowering the patient and improving outcome.

    abstract::Inflammatory bowel disease, in common with most chronic diseases, is managed by specialist clinicians during regular clinic follow-up visits. Patients spend approximately 1 h per year with clinicians, with few provisions made for patient participation in their own management for the remainder of the year, resulting in...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02061.x

    authors: Robinson A

    更新日期:2004-10-01 00:00:00

  • Review article: definition and diagnosis in portal hypertension--continued problems with the Baveno consensus?

    abstract::The goals of the Baveno workshops were to develop consensus definitions of key events related to portal hypertension and variceal bleeding, and to produce guidelines to facilitate the conduct and reporting of clinical trials. The consensus definitions concern the diagnosis of active bleeding, failure to control bleedi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02108.x

    authors: de Franchis R

    更新日期:2004-09-01 00:00:00

  • The effects of omeprazole and cimetidine on duodenal ulcer healing and the relief of symptoms.

    abstract::In a Swedish double-blind multicentre study, omeprazole (30 mg o.m.) was compared with the H2-receptor antagonist cimetidine (400 mg b.d.) in 152 patients. Clinical assessments and laboratory investigations were carried out at 2 and 4 weeks, and again at 6 weeks in unhealed patients. Endoscopy was performed at 2 weeks...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.1988.tb00721.x

    authors: Dahlgren S,Domellöf L,Hradsky M,Norryd C,Brunkwall J,Svensson G,Svensson JO,Karlsson J,Knutson U,Gasslander T

    更新日期:1988-12-01 00:00:00

  • Review article: maintenance treatment of Crohn's disease.

    abstract::The aetiology of Crohn's disease is unknown and therefore no curative treatments are available for the disease. The natural history of Crohn's disease is characterized by recurrent flare-ups of symptoms. Several drug treatments are effective in inducing clinical remission. However, no drug treatments are available in ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.17.s2.20.x

    authors: Biancone L,Tosti C,Fina D,Fantini M,De Nigris F,Geremia A,Pallone F

    更新日期:2003-06-01 00:00:00

  • Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings.

    abstract:BACKGROUND:Faecal calprotectin and lactoferrin increasingly serve as surrogate markers of disease activity in IBD. Data on the correlation of these markers with simple endoscopic score for Crohn's disease (SES-CD) and with histological findings are as yet limited. Aim To study the correlation of faecal calprotectin and...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2008.03835.x

    authors: Sipponen T,Kärkkäinen P,Savilahti E,Kolho KL,Nuutinen H,Turunen U,Färkkilä M

    更新日期:2008-11-15 00:00:00

  • Systematic review: are lymphocytic colitis and collagenous colitis two subtypes of the same disease - microscopic colitis?

    abstract:BACKGROUND:Despite similar clinical symptoms, collagenous colitis (CC) and lymphocytic colitis (LC) are considered two distinct disease entities. AIM:To compare pathoanatomical findings, clinical presentations, risk factors, course of diseases and response to treatment in CC and LC to establish whether they could be s...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2012.05166.x

    authors: Rasmussen MA,Munck LK

    更新日期:2012-07-01 00:00:00

  • Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.

    abstract:BACKGROUND:Adverse events leading to discontinuation or dose reduction of thiopurine therapy occur in 9-28% of patients with inflammatory bowel disease. AIMS:To evaluate the influence of thiopurine methyltransferase status and thiopurine metabolites in a large patient population for the risk of developing adverse even...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2006.02977.x

    authors: Hindorf U,Lindqvist M,Hildebrand H,Fagerberg U,Almer S

    更新日期:2006-07-15 00:00:00

  • The effect of omeprazole on gastric juice viscosity, pH and bacterial counts.

    abstract:BACKGROUND:In vitro studies have shown that pH is an important determinant of mucus structure and function, but the relationship in vivo is unclear. Omeprazole increases intragastric pH and also allows bacterial overgrowth. In this study we have assessed the effect of omeprazole on gastric juice viscosity and examined ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1996.tb00183.x

    authors: Goddard AF,Spiller RC

    更新日期:1996-02-01 00:00:00

  • Randomised clinical trial: enteral nutrition does not improve the long-term outcome of alcoholic cirrhotic patients with jaundice.

    abstract:BACKGROUND:Malnutrition and jaundice are independent prognostic factors in cirrhosis. AIM:To assess the impact of enteral nutrition on the survival of alcoholic cirrhotic patients with jaundice but without acute alcoholic hepatitis. METHODS:The study was a multicentre prospective randomised controlled trial comparing...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2012.05075.x

    authors: Dupont B,Dao T,Joubert C,Dupont-Lucas C,Gloro R,Nguyen-Khac E,Beaujard E,Mathurin P,Vastel E,Musikas M,Ollivier I,Piquet MA

    更新日期:2012-05-01 00:00:00

  • Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III.

    abstract:BACKGROUND:The agreement between subtyping irritable bowel syndrome (IBS) patients based on Rome II criteria versus Rome III criteria is unknown. AIM:To compare IBS subtyping based on Rome II versus III criteria. METHODS:The Rome II Modular Questionnaire and the Bristol Stool Form Scale (one-week diary cards) were co...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2007.03422.x

    authors: Ersryd A,Posserud I,Abrahamsson H,Simrén M

    更新日期:2007-09-15 00:00:00

  • Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux.

    abstract:AIM:To assess the efficacy and tolerance of sodium alginate compared to cisapride in patients suffering from reflux symptoms, without severe oesophagitis. METHODS:A total of 353 patients with symptoms of reflux oesophagitis (average age 40 years, 51% men, 33% smokers, 43% consumers of alcoholic drinks) were selected a...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.1998.00283.x

    authors: Poynard T,Vernisse B,Agostini H

    更新日期:1998-02-01 00:00:00

  • Cyclo-oxygenase-2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study.

    abstract:BACKGROUND:The incidence of Barrett's oesophageal adenocarcinoma is increasing more rapidly than any other malignancy in industrialized countries. Cyclo-oxygenase-2 appears to play an important role in gastrointestinal carcinogenesis. Previous studies on cyclo-oxygenase-2 expression in Barrett's oesophageal carcinogene...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2003.01432.x

    authors: Cheong E,Igali L,Harvey I,Mole M,Lund E,Johnson IT,Rhodes M

    更新日期:2003-02-01 00:00:00

  • Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey.

    abstract:BACKGROUND:Although the use of tumour necrosis factor (TNF) antagonists is increasingly codified, several unresolved issues remain. AIM:To conduct a French national survey on TNF antagonists use in inflammatory bowel disease (IBD). METHODS:A postal questionnaire was sent to all French gastroenterologists among whom 4...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2009.04097.x

    authors: Oussalah A,Roblin X,Laharie D,Filippi J,Flamant M,Faure P,Phelip JM,Bigard MA,Peyrin-Biroulet L

    更新日期:2009-10-15 00:00:00